Hamou, M.F.

patient glioblastoma tumor gefitinib cancer tissue treatment analysis study sample pathway trial gbm-o expression mutation survival fication factor group oligodendroglioma-like component effect amplification research glioma table receptor association phase prognostic status feature number component gefitinib treatment neuropathol oncol department concentration lausanne phospho-protein growth phosphorylation university necrosis idh 1 mutations kinase bs -153 xenografts outcome tumor tissue month signi presence value epidermal xenograft subtype plasma cancer therapeutics downloaded mgmt methylation status phase ii trial diagnosis classi classi fication onlinefirst protein inhibitor pathology american april article cancer research -153 survival group signi ficantly egfrviii review transductor signal model lausanne university hospital